BACKGROUND: Improved diagnostic tests for tuberculosis in children are needed. We hypothesized that transcriptional signatures of host blood could be used to distinguish tuberculosis from other diseases in African children who either were or were not infected with the human immunodeficiency virus (HIV). METHODS: The study population comprised prospective cohorts of children who were undergoing evaluation for suspected tuberculosis in South Africa (655 children), Malawi (701 children), and Kenya (1599 children). Patients were assigned to groups according to whether the diagnosis was culture-confirmed tuberculosis, culture-negative tuberculosis, diseases other than tuberculosis, or latent tuberculosis infection. Diagnostic signatures distinguishing tuberculosis from other diseases and from latent tuberculosis infection were identified from genomewide analysis of RNA expression in host blood. RESULTS: We identified a 51-transcript signature distinguishing tuberculosis from other diseases in the South African and Malawian children (the discovery cohort). In the Kenyan children (the validation cohort), a risk score based on the signature for tuberculosis and for diseases other than tuberculosis showed a sensitivity of 82.9% (95% confidence interval [CI], 68.6 to 94.3) and a specificity of 83.6% (95% CI, 74.6 to 92.7) for the diagnosis of culture-confirmed tuberculosis. Among patients with cultures negative for Mycobacterium tuberculosis who were treated for tuberculosis (those with highly probable, probable, or possible cases of tuberculosis), the estimated sensitivity was 62.5 to 82.3%, 42.1 to 80.8%, and 35.3 to 79.6%, respectively, for different estimates of actual tuberculosis in the groups. In comparison, the sensitivity of the Xpert MTB/RIF assay for molecular detection of M. tuberculosis DNA in cases of culture-confirmed tuberculosis was 54.3% (95% CI, 37.1 to 68.6), and the sensitivity in highly probable, probable, or possible cases was an estimated 25.0 to 35.7%, 5.3 to 13.3%, and 0%, respectively; the specificity of the assay was 100%. CONCLUSIONS: RNA expression signatures provided data that helped distinguish tuberculosis from other diseases in African children with and those without HIV infection. (Funded by the European Union Action for Diseases of Poverty Program and others).
BACKGROUND: Improved diagnostic tests for tuberculosis in children are needed. We hypothesized that transcriptional signatures of host blood could be used to distinguish tuberculosis from other diseases in African children who either were or were not infected with the human immunodeficiency virus (HIV). METHODS: The study population comprised prospective cohorts of children who were undergoing evaluation for suspected tuberculosis in South Africa (655 children), Malawi (701 children), and Kenya (1599 children). Patients were assigned to groups according to whether the diagnosis was culture-confirmed tuberculosis, culture-negative tuberculosis, diseases other than tuberculosis, or latent tuberculosis infection. Diagnostic signatures distinguishing tuberculosis from other diseases and from latent tuberculosis infection were identified from genomewide analysis of RNA expression in host blood. RESULTS: We identified a 51-transcript signature distinguishing tuberculosis from other diseases in the South African and Malawian children (the discovery cohort). In the Kenyan children (the validation cohort), a risk score based on the signature for tuberculosis and for diseases other than tuberculosis showed a sensitivity of 82.9% (95% confidence interval [CI], 68.6 to 94.3) and a specificity of 83.6% (95% CI, 74.6 to 92.7) for the diagnosis of culture-confirmed tuberculosis. Among patients with cultures negative for Mycobacterium tuberculosis who were treated for tuberculosis (those with highly probable, probable, or possible cases of tuberculosis), the estimated sensitivity was 62.5 to 82.3%, 42.1 to 80.8%, and 35.3 to 79.6%, respectively, for different estimates of actual tuberculosis in the groups. In comparison, the sensitivity of the Xpert MTB/RIF assay for molecular detection of M. tuberculosis DNA in cases of culture-confirmed tuberculosis was 54.3% (95% CI, 37.1 to 68.6), and the sensitivity in highly probable, probable, or possible cases was an estimated 25.0 to 35.7%, 5.3 to 13.3%, and 0%, respectively; the specificity of the assay was 100%. CONCLUSIONS: RNA expression signatures provided data that helped distinguish tuberculosis from other diseases in African children with and those without HIV infection. (Funded by the European Union Action for Diseases of Poverty Program and others).
Authors: Rohit Mistry; Jacqueline M Cliff; Christopher L Clayton; Nulda Beyers; Yasmin S Mohamed; Paul A Wilson; Hazel M Dockrell; Don M Wallace; Paul D van Helden; Ken Duncan; Pauline T Lukey Journal: J Infect Dis Date: 2006-12-21 Impact factor: 5.226
Authors: Chifumbe Chintu; Victor Mudenda; Sebastian Lucas; Andrew Nunn; Kennedy Lishimpi; Daniel Maswahu; Francis Kasolo; Peter Mwaba; Ganapati Bhat; Hiroshi Terunuma; Alimuddin Zumla Journal: Lancet Date: 2002-09-28 Impact factor: 79.321
Authors: Jeroen Maertzdorf; January Weiner; Hans-Joachim Mollenkopf; Torsten Bauer; Antje Prasse; Joachim Müller-Quernheim; Stefan H E Kaufmann Journal: Proc Natl Acad Sci U S A Date: 2012-04-30 Impact factor: 11.205
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: B Kampmann; E Whittaker; A Williams; S Walters; A Gordon; N Martinez-Alier; B Williams; A M Crook; A-M Hutton; S T Anderson Journal: Eur Respir J Date: 2009-02-05 Impact factor: 16.671
Authors: Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra Journal: Nature Date: 2010-08-19 Impact factor: 49.962
Authors: Lilly M Verhagen; Aldert Zomer; Mailis Maes; Julian A Villalba; Berenice Del Nogal; Marc Eleveld; Sacha Aft van Hijum; Jacobus H de Waard; Peter Wm Hermans Journal: BMC Genomics Date: 2013-02-01 Impact factor: 3.969
Authors: Rewa K Choudhary; Kristin M Wall; Irene Njuguna; Patricia B Pavlinac; Sylvia M LaCourse; Vincent Otieno; John Gatimu; Joshua Stern; Elizabeth Maleche-Obimbo; Dalton Wamalwa; Grace John-Stewart; Lisa M Cranmer Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Bareng A S Nonyane; Mark P Nicol; Nicholas J Andreas; Stefanie Rimmele; Nicole Schneiderhan-Marra; Lesley J Workman; Mark D Perkins; Thomas Joos; Tobias Broger; Jerrold J Ellner; David Alland; Beate Kampmann; Susan E Dorman; Heather J Zar Journal: Pediatr Infect Dis J Date: 2018-01 Impact factor: 2.129
Authors: N Satproedprai; N Wichukchinda; S Suphankong; W Inunchot; T Kuntima; S Kumpeerasart; S Wattanapokayakit; S Nedsuwan; H Yanai; K Higuchi; N Harada; S Mahasirimongkol Journal: Genes Immun Date: 2015-03-12 Impact factor: 2.676
Authors: Santtu Heinonen; Tuomas Jartti; Carla Garcia; Silvia Oliva; Cynthia Smitherman; Esperanza Anguiano; Wouter A A de Steenhuijsen Piters; Tytti Vuorinen; Olli Ruuskanen; Blerta Dimo; Nicolas M Suarez; Virginia Pascual; Octavio Ramilo; Asuncion Mejias Journal: Am J Respir Crit Care Med Date: 2016-04-01 Impact factor: 21.405